Exelixis Inc (EXEL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-03..
Quick ratio
Overview →Financial period ending 2026-07-03; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-03. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 361.93M USD | Liabilities, Current |
| Cash and equivalents | 281.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 557.94M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 28.73M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-07-03 | (m) | $361.93M | $281.45M | $557.94M | (m) | $28.73M | (m) |
| 2026-04-03 | (m) | $370.98M | $226.15M | $551.05M | (m) | $26.61M | (m) |
| 2026-01-02 | (m) | $405.64M | $482.49M | $576.60M | (m) | $21.69M | (m) |
| 2025-10-03 | (m) | $373.78M | $376.30M | $612.24M | (m) | $27.40M | (m) |
| 2025-07-04 | (m) | $336.11M | $164.43M | $626.66M | (m) | $23.48M | (m) |
| 2025-04-04 | (m) | $399.10M | $183.75M | $847.56M | (m) | $24.85M | (m) |
| 2025-01-03 | (m) | $403.77M | $217.37M | $893.90M | (m) | $22.39M | (m) |
| 2024-09-27 | (m) | $394.35M | $258.35M | $930.82M | (m) | $21.01M | (m) |
| 2024-06-28 | (m) | $345.70M | $198.46M | (m) | (m) | $20.61M | (m) |
| 2024-03-29 | (m) | $373.01M | $259.56M | (m) | (m) | $21.11M | (m) |
| 2023-12-29 | (m) | $394.28M | $262.99M | (m) | (m) | $17.32M | (m) |
| 2023-09-29 | (m) | $376.82M | $396.86M | (m) | (m) | $24.98M | (m) |
| 2023-06-30 | (m) | $339.62M | $464.48M | (m) | (m) | $28.64M | (m) |
| 2023-03-31 | (m) | $327.60M | $540.60M | (m) | (m) | $29.91M | (m) |
| 2022-12-30 | (m) | $324.36M | $501.19M | (m) | (m) | $33.30M | (m) |
| 2022-09-30 | (m) | $301.73M | $675.29M | (m) | (m) | $26.71M | (m) |
| 2022-07-01 | (m) | $304.52M | $627.00M | (m) | (m) | $33.02M | (m) |
| 2022-04-01 | (m) | $289.08M | $723.27M | (m) | (m) | $28.47M | (m) |
| 2021-12-31 | (m) | $337.59M | $647.17M | (m) | (m) | $27.49M | (m) |
| 2021-10-01 | (m) | $269.51M | $567.33M | (m) | (m) | $28.24M | (m) |
| 2021-07-02 | (m) | $255.33M | $492.46M | (m) | (m) | $24.98M | (m) |
| 2021-04-02 | (m) | $213.34M | $370.21M | (m) | (m) | $24.76M | (m) |
| 2021-01-01 | (m) | $204.66M | $319.22M | (m) | (m) | $20.97M | (m) |
| 2020-10-02 | (m) | $201.34M | $334.05M | (m) | (m) | $19.32M | (m) |
| 2020-07-03 | (m) | $142.68M | $527.14M | (m) | (m) | $16.61M | (m) |
| 2020-04-03 | (m) | $140.48M | $357.34M | (m) | (m) | $15.42M | (m) |
| 2020-01-03 | (m) | $142.75M | $266.50M | (m) | (m) | $12.89M | (m) |
| 2019-09-27 | (m) | $141.07M | $242.32M | (m) | (m) | $13.37M | (m) |
| 2019-06-28 | (m) | $110.80M | $369.79M | (m) | (m) | $12.35M | (m) |
| 2019-03-29 | (m) | $125.13M | $373.94M | (m) | (m) | $10.14M | (m) |
| 2018-12-28 | (m) | $105.47M | $314.77M | (m) | (m) | $9.84M | (m) |
| 2018-09-28 | (m) | $90.91M | $353.62M | (m) | (m) | $10.43M | (m) |
| 2018-06-29 | (m) | $99.94M | $248.41M | (m) | (m) | $8.37M | (m) |
| 2018-03-30 | (m) | $84.86M | $232.33M | (m) | (m) | $7.56M | (m) |
| 2017-12-29 | (m) | $115.17M | $183.16M | (m) | (m) | $6.66M | (m) |
| 2017-09-30 | (m) | $108.95M | $149.36M | (m) | (m) | $5.81M | (m) |
| 2017-09-29 | (m) | (m) | $149.36M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $97.67M | $135.21M | (m) | (m) | $5.42M | (m) |
| 2017-03-31 | (m) | $202.29M | $183.18M | (m) | (m) | $3.30M | (m) |
| 2016-12-31 | (m) | $270.59M | $151.69M | (m) | (m) | $3.34M | (m) |
| 2016-12-30 | (m) | $268.79M | $151.69M | (m) | (m) | $3.34M | (m) |
| 2016-09-30 | (m) | $201.64M | $111.22M | (m) | (m) | $3.29M | (m) |
| 2016-06-30 | (m) | $192.79M | $129.83M | (m) | (m) | $2.81M | (m) |
| 2016-03-31 | (m) | $101.07M | $276.88M | (m) | (m) | $2.47M | (m) |
| 2016-01-01 | (m) | (m) | $141.63M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $52.25M | $141.63M | (m) | (m) | $2.62M | (m) |
| 2015-09-30 | (m) | $55.92M | $145.64M | (m) | (m) | $2.12M | (m) |
| 2015-06-30 | (m) | $60.32M | $61.95M | (m) | (m) | $2.61M | (m) |
| 2015-03-31 | (m) | $58.68M | $84.99M | (m) | (m) | $2.59M | (m) |
| 2015-01-02 | (m) | (m) | $80.39M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $171.86M | $80.39M | (m) | (m) | $2.38M | (m) |
| 2014-09-30 | (m) | $173.91M | $100.06M | (m) | (m) | $3.88M | (m) |
| 2014-06-30 | (m) | $171.86M | $147.34M | (m) | (m) | $3.03M | (m) |
| 2014-03-31 | (m) | $71.06M | $157.54M | (m) | (m) | $2.69M | (m) |
| 2013-12-31 | (m) | $87.85M | $103.98M | (m) | (m) | $2.89M | (m) |
| 2013-09-30 | (m) | $77.88M | $92.02M | (m) | (m) | $1.76M | (m) |
| 2013-06-30 | (m) | $74.60M | $131.77M | (m) | (m) | $681.00K | (m) |
| 2013-03-31 | (m) | $67.80M | $171.23M | (m) | (m) | $280.00K | (m) |
| 2012-12-31 | (m) | $81.70M | $170.07M | $241.37M | (m) | $0.00 | (m) |
| 2012-09-30 | (m) | $85.42M | $308.81M | $163.54M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $90.15M | $68.14M | $138.90M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $87.46M | $70.47M | $172.98M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $92.33M | $74.26M | $120.00M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $166.62M | $66.21M | $156.95M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $193.54M | $75.28M | $187.50M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $202.05M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $199.94M | $97.44M | $65.22M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $95.34M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $157.20M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $86.80M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $247.70M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |